###begin article-title 0
###xml 23 28 <span type="species:ncbi:9606">human</span>
TDP-43 is a culprit in human neurodegeneration, and not just an innocent bystander
###end article-title 0
###begin p 1
###xml 126 131 <span type="species:ncbi:9606">human</span>
In 2006 the protein TDP-43 was identified as the major ubiquitinated component deposited in the inclusion bodies found in two human neurodegenerative diseases, amyotrophic lateral sclerosis and frontotemporal lobar degeneration. The pathogenesis of both disorders is unclear, although they are related by having some overlap of symptoms and now by the shared histopathology of TDP-43 deposition. Now, in 2008, several papers have been published in quick succession describing mutations in the TDP-43 gene, showing they can be a primary cause of amyotrophic lateral sclerosis. There are many precedents in neurodegenerative disease in which rare single-gene mutations have given great insight into understanding disease processes, which is why the TDP-43 mutations are potentially very important.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
Rapidly rising life expectancy is forcing many of the world's societies to see neurodegenerative diseases as a wider social and economic issue. Such diseases have always been devastating for sufferers and their carers, but aging societies are facing a broader burden resulting from the lack of effective treatments. There is hope for disorders such as Alzheimer disease (AD), where now we have a good understanding of pathogenesis and novel treatments are on the horizon. However, two neurodegenerative disorders that remain in urgent need of attention, and that mainly but not exclusively affect the aging population, are amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).
###end p 3
###begin p 4
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2006</xref>
###xml 214 218 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">2006</xref>
###xml 605 609 605 609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2006</xref>
###xml 631 635 631 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">2006</xref>
###xml 653 657 653 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">2007</xref>
###xml 681 685 681 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">2008</xref>
###xml 976 980 976 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">1993</xref>
###xml 995 999 995 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">1993</xref>
###xml 1069 1073 1069 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">2006</xref>
###xml 1225 1229 1225 1229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2006</xref>
###xml 1251 1255 1251 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">2006</xref>
###xml 1273 1277 1273 1277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">2007</xref>
###xml 1301 1305 1301 1305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">2008</xref>
ALS is the third most common neurodegenerative cause of adult death after AD and Parkinson disease () and the lifetime risk of dying from ALS lies between 1/400 and 1/1000 (Boillee et al. 2006; Pasinelli and Brown 2006), and in the UK 1 in 400 death certificates is issued for "motor neuron disease" (J. Stevens, personal communication). In ALS the upper motor neurons that run from the brain into the spinal cord and the lower motor neurons that extend from the spinal cord out to the muscles degenerate, leading inexorably to paralysis and death, typically within 3-5 years of diagnosis (Boillee et al. 2006; Pasinelli and Brown 2006; Schymick et al. 2007; Valdmanis and Rouleau 2008). Intellect usually remains intact and no effective treatments are available. Up to approximately 10% of ALS is familial (FALS), usually autosomal dominant, and mutations in the ubiquitously expressed enzyme superoxide dismutase 1 (SOD1) are causative in less than 20% of FALS (Deng et al. 1993; Rosen et al. 1993) and in approximately 1% of sporadic ALS (SALS) (Pasinelli and Brown 2006). Other rare ALS mutant genes are known, usually associated with variants of ALS rather than the classic typical midlife onset disease (Boillee et al. 2006; Pasinelli and Brown 2006; Schymick et al. 2007; Valdmanis and Rouleau 2008).
###end p 4
###begin p 5
###xml 100 104 100 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2007</xref>
###xml 120 124 120 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2003</xref>
###xml 144 148 144 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">2002</xref>
###xml 440 444 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">1998</xref>
###xml 633 637 633 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">1998</xref>
###xml 654 658 654 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">1998</xref>
###xml 679 683 679 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR46">1998</xref>
###xml 726 732 726 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHMP2B</italic>
###xml 752 756 752 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">2005</xref>
###xml 776 779 776 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GRN</italic>
###xml 795 799 795 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">2006</xref>
###xml 814 818 814 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">2006</xref>
###xml 923 926 923 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VCP</italic>
###xml 1111 1115 1111 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR52">2004</xref>
FTLD is the most common cause of presenile (below 65 years of age) dementia after AD (Forman et al. 2007; Harvey et al. 2003; Ratnavalli et al. 2002). Affected individuals have a range of characteristic traits that reflect degeneration in the frontal and temporal lobes of the brain-the areas that control behavior, emotions, and language. Early symptoms typically manifest as language difficulties and inappropriate behavior (Neary et al. 1998). Up to 40% of FTLD is thought to be familial with genetically heterogeneous causes. Causative mutations have been identified in several genes, including those encoding tau (Hutton et al. 1998; Poorkaj et al. 1998; Spillantini et al. 1998), charged multivesicular body protein 2B (CHMP2B) (Skibinski et al. 2005), and progranulin (GRN) (Baker et al. 2006; Cruts et al. 2006), and others remain to be found. Mutations have also been identified in the valosin-containing protein (VCP) gene in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia, in which frontotemporal dementia can be, but is not always, a feature (Watts et al. 2004).
###end p 5
###begin p 6
###xml 209 213 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR50">2008</xref>
###xml 234 238 234 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">2008</xref>
###xml 345 349 345 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">2006</xref>
###xml 368 372 368 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR49">2007</xref>
###xml 451 455 451 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">1993</xref>
###xml 558 562 558 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">2008</xref>
###xml 639 643 639 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">2008</xref>
###xml 429 437 <span type="species:ncbi:9606">patients</span>
At first glance ALS and FTLD appear to be different disorders; however, clinicians have noted for some time that there are overlaps. FTLD symptoms are reported in up to 20% of ALS cases (Valdmanis and Rouleau 2008; Van Deerlin et al. 2008) and there are other intriguing connections such as families that segregate both disorders (Morita et al. 2006; Valdmanis et al. 2007) and imaging studies which show frontal deficits in ALS patients (Kato et al. 1993). A recent study has shown that progranulin is a modifier of ALS disease progression (Sleegers et al. 2008), although this was not replicated in another study (Pickering-Brown et al. 2008).
###end p 6
###begin p 7
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD1</italic>
###xml 379 383 379 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2006</xref>
###xml 405 409 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">2006</xref>
###xml 670 674 670 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PGRN</italic>
###xml 676 679 676 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VCP</italic>
###xml 685 691 685 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHMP2B</italic>
###xml 740 744 740 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">2007</xref>
###xml 304 319 <span type="species:ncbi:10090">transgenic mice</span>
Importantly, in common with several other neurodegenerative disorders, ALS and FTLD both present with aggregates of misfolded proteins in the cytoplasm and/or nucleus of neurons. Ubiquitinated inclusion bodies have been reported in the cytoplasm of neurons of both SALS and FALS cases and in mutant SOD1 transgenic mice that model FALS (for further discussion see Boillee et al. 2006; Pasinelli and Brown 2006). FTLD is subdivided into two classes based on the content of the inclusion bodies: (1) those with tau-positive and ubiquitin-negative inclusions (tauopathies) and (2) more common forms with ubiquitinated but tau-negative inclusions known as FTLD-U, including PGRN, VCP, and CHMP2B mutations (reviewed in Mackenzie and Rademakers 2007). ALS and FTLD-U cases both present with cytoplasmic ubiquitin-positive, tau-negative inclusions indicating that there are at least some common pathway(s) involved in the pathogenesis of these diseases.
###end p 7
###begin title 8
###xml 0 31 0 31 <bold xmlns:xlink="http://www.w3.org/1999/xlink">TDP-43&#8212;the new kid on the block</bold>
TDP-43-the new kid on the block
###end title 8
###begin p 9
###xml 358 362 358 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">2006</xref>
###xml 406 410 406 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2006</xref>
###xml 588 592 588 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">2007</xref>
###xml 607 611 607 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">2008</xref>
###xml 627 631 627 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">2008</xref>
###xml 861 865 861 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2007</xref>
###xml 882 886 882 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2008</xref>
###xml 901 905 901 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">2008</xref>
###xml 923 927 923 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2007</xref>
###xml 944 948 944 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2007</xref>
###xml 974 978 974 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">2007</xref>
###xml 995 999 995 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">2007</xref>
Research into ALS and FTLD-U was radically redirected by the appearance of a new player in 2006. In that year, Neumann, Trojanowski, Lee, and colleagues provided a molecular connection between these disorders by finding that a protein called the TAR DNA-binding protein (TDP-43) is the major protein in the inclusion bodies in both disorders (Neumann et al. 2006), which was quickly confirmed (Arai et al. 2006). Some authors now refer to the TDP-43 inclusion positive types of ALS and FTLD-U as different forms of the same neurodegenerative disorder: TDP-43 proteinopathy (Cairns et al. 2007; Kwong et al. 2008; Winton et al. 2008). TDP-43 positive inclusions have now also been reported in cases of Alzheimer disease, Pick disease, dementia with Lewy bodies, and other neurodegenerative disorders, and are seen in glia as well as neurons (Amador-Ortiz et al. 2007; Freeman et al. 2008; Geser et al. 2008; Hasegawa et al. 2007; Higashi et al. 2007; Nakashima-Yasuda et al. 2007; Neumann et al. 2007).
###end p 9
###begin p 10
###xml 149 153 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">1995</xref>
###xml 274 280 274 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TARDBP</italic>
###xml 393 394 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 645 649 645 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2005</xref>
###xml 651 655 651 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">2008</xref>
###xml 672 676 672 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2001</xref>
###xml 693 697 693 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">2008</xref>
###xml 713 717 713 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">2008</xref>
###xml 916 920 916 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">2006</xref>
###xml 1243 1247 1231 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">2006</xref>
###xml 1263 1267 1251 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR53">2008</xref>
###xml 1403 1407 1391 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2007</xref>
###xml 1410 1416 1398 1404 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 2031 2035 2019 2023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2008</xref>
###xml 2052 2056 2040 2044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2008</xref>
###xml 2076 2080 2064 2068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">2008</xref>
###xml 2101 2105 2089 2093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">2008</xref>
###xml 2123 2127 2111 2115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">2008</xref>
###xml 1416 2128 1404 2116 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="11">TDP-43 mutations in ALS. TDP-43 is encoded by a 6-exon gene, of which exons 2-6 are protein coding (top). The TDP-43 protein contains four known functional domains: a nuclear localization sequence, two central RNA Recognition Motifs (RRM1 and RRM2), and a C-terminal glycine-rich domain, predicted to mediate protein-protein interactions. All disease mutations so far are found in the glycine-rich domain (encoded by exon 6), with the exception of one mutation in RRM1 (encoded by exon 4). A mutation in the nuclear localization domain has been reported in two unaffected controls (data compiled from Gitcho et&#160;al. <xref ref-type="bibr" rid="CR17">2008</xref>; Kabashi et&#160;al. <xref ref-type="bibr" rid="CR24">2008</xref>; Sreedharan et&#160;al. <xref ref-type="bibr" rid="CR47">2008</xref>; Van Deerlin et&#160;al. <xref ref-type="bibr" rid="CR51">2008</xref>; Yokoseki et&#160;al. <xref ref-type="bibr" rid="CR54">2008</xref>)</p>
###xml 1416 2128 1404 2116 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="11">TDP-43 mutations in ALS. TDP-43 is encoded by a 6-exon gene, of which exons 2-6 are protein coding (top). The TDP-43 protein contains four known functional domains: a nuclear localization sequence, two central RNA Recognition Motifs (RRM1 and RRM2), and a C-terminal glycine-rich domain, predicted to mediate protein-protein interactions. All disease mutations so far are found in the glycine-rich domain (encoded by exon 6), with the exception of one mutation in RRM1 (encoded by exon 4). A mutation in the nuclear localization domain has been reported in two unaffected controls (data compiled from Gitcho et&#160;al. <xref ref-type="bibr" rid="CR17">2008</xref>; Kabashi et&#160;al. <xref ref-type="bibr" rid="CR24">2008</xref>; Sreedharan et&#160;al. <xref ref-type="bibr" rid="CR47">2008</xref>; Van Deerlin et&#160;al. <xref ref-type="bibr" rid="CR51">2008</xref>; Yokoseki et&#160;al. <xref ref-type="bibr" rid="CR54">2008</xref>)</p></caption>
###xml 2128 2128 2116 2116 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="335_2008_9117_Fig1_HTML" id="MO1"/>
###xml 1410 2128 1398 2116 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="11">TDP-43 mutations in ALS. TDP-43 is encoded by a 6-exon gene, of which exons 2-6 are protein coding (top). The TDP-43 protein contains four known functional domains: a nuclear localization sequence, two central RNA Recognition Motifs (RRM1 and RRM2), and a C-terminal glycine-rich domain, predicted to mediate protein-protein interactions. All disease mutations so far are found in the glycine-rich domain (encoded by exon 6), with the exception of one mutation in RRM1 (encoded by exon 4). A mutation in the nuclear localization domain has been reported in two unaffected controls (data compiled from Gitcho et&#160;al. <xref ref-type="bibr" rid="CR17">2008</xref>; Kabashi et&#160;al. <xref ref-type="bibr" rid="CR24">2008</xref>; Sreedharan et&#160;al. <xref ref-type="bibr" rid="CR47">2008</xref>; Van Deerlin et&#160;al. <xref ref-type="bibr" rid="CR51">2008</xref>; Yokoseki et&#160;al. <xref ref-type="bibr" rid="CR54">2008</xref>)</p></caption><graphic position="anchor" xlink:href="335_2008_9117_Fig1_HTML" id="MO1"/></fig>
###xml 109 137 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 284 289 <span type="species:ncbi:9606">human</span>
TDP-43 is a 414-residue, 43-kDa protein, first identified as a binding partner of the TAR DNA element of the human immunodeficiency virus (Ou et al. 1995). Currently we know that TDP-43 is a ubiquitously expressed, highly conserved nuclear protein encoded by a 6-exon gene (TARDBP on human chromosome 1p36.2). The protein consists of two RNA recognition motifs and a glycine-rich domain (Fig. 1). It is found in nuclear bodies, colocalized with SMN and gemin proteins, and may function as a transcriptional repressor and as an activator of exon skipping, or in other roles such as in miRNA biogenesis, apoptosis, and cell division (Ayala et al. 2005, 2008; Buratti et al. 2001; Johnson et al. 2008; Winton et al. 2008). In the TDP-43 proteinopathies TDP-43 is depleted from the nucleus and is sequestered as hyperphosphorylated insoluble aggregates in the nucleus, perikarya, and dystrophic neurites (Neumann et al. 2006). Perturbation of the trafficking of TDP-43 between the nucleus and cytoplasm is thought to lead to the formation of these aggregates; brain samples from both ALS and FTLD-U are enriched for a smaller (approximately25 kDa) phosphorylated C-terminal fragment and high-molecular-weight ubiquitinated species (Neumann et al. 2006; Winton et al. 2008). Inhibition of autophagy can also lead to the relocalization of TDP-43 from the nucleus to the cytoplasm in vitro (Filimonenko et al. 2007). Fig. 1TDP-43 mutations in ALS. TDP-43 is encoded by a 6-exon gene, of which exons 2-6 are protein coding (top). The TDP-43 protein contains four known functional domains: a nuclear localization sequence, two central RNA Recognition Motifs (RRM1 and RRM2), and a C-terminal glycine-rich domain, predicted to mediate protein-protein interactions. All disease mutations so far are found in the glycine-rich domain (encoded by exon 6), with the exception of one mutation in RRM1 (encoded by exon 4). A mutation in the nuclear localization domain has been reported in two unaffected controls (data compiled from Gitcho et al. 2008; Kabashi et al. 2008; Sreedharan et al. 2008; Van Deerlin et al. 2008; Yokoseki et al. 2008)
###end p 10
###begin p 11
###xml 615 619 615 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2008</xref>
###xml 636 640 636 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2008</xref>
###xml 660 664 660 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">2008</xref>
###xml 685 689 685 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">2008</xref>
###xml 707 711 707 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">2008</xref>
TDP-43 mutations in ALS. TDP-43 is encoded by a 6-exon gene, of which exons 2-6 are protein coding (top). The TDP-43 protein contains four known functional domains: a nuclear localization sequence, two central RNA Recognition Motifs (RRM1 and RRM2), and a C-terminal glycine-rich domain, predicted to mediate protein-protein interactions. All disease mutations so far are found in the glycine-rich domain (encoded by exon 6), with the exception of one mutation in RRM1 (encoded by exon 4). A mutation in the nuclear localization domain has been reported in two unaffected controls (data compiled from Gitcho et al. 2008; Kabashi et al. 2008; Sreedharan et al. 2008; Van Deerlin et al. 2008; Yokoseki et al. 2008)
###end p 11
###begin p 12
###xml 128 132 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">2008</xref>
###xml 149 153 149 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">2006</xref>
###xml 217 221 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">2007</xref>
###xml 234 238 234 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR48">2007</xref>
###xml 250 254 250 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD1</italic>
###xml 254 258 254 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G93A</italic>
###xml 254 258 254 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>G93A</italic></sup>
###xml 260 264 260 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD1</italic>
###xml 264 268 264 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G37R</italic>
###xml 264 268 264 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>G37R</italic></sup>
###xml 274 278 274 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD1</italic>
###xml 278 282 278 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G85R</italic>
###xml 278 282 278 282 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>G85R</italic></sup>
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2007</xref>
###xml 294 299 <span type="species:ncbi:10090">mouse</span>
Intriguingly, while TDP-43 is deposited in sporadic and familial FTLD-U and in sporadic and non-SOD1 familial ALS (Kwong et al. 2008; Neumann et al. 2006), it is not found in inclusions in SOD1 FALS (Mackenzie et al. 2007; Tan et al. 2007) or in the SOD1G93A, SOD1G37R, and SOD1G85R transgenic mouse models of FALS (Robertson et al. 2007).
###end p 12
###begin title 13
TDP-43 is a criminal, not just a bystander
###end title 13
###begin p 14
###xml 232 236 232 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">2007</xref>
###xml 255 259 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">2007</xref>
###xml 279 283 279 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">2007</xref>
###xml 362 373 362 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">consequence</italic>
###xml 461 466 461 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cause</italic>
###xml 725 729 725 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2008</xref>
###xml 746 750 746 750 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2008</xref>
###xml 770 774 770 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">2008</xref>
###xml 795 799 795 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">2008</xref>
###xml 817 821 817 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">2008</xref>
###xml 841 842 841 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 850 851 850 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1195 1199 1195 1199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2008</xref>
###xml 1410 1414 1410 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">2008</xref>
###xml 1432 1436 1432 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">2008</xref>
###xml 1439 1446 1439 1446 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1446 1489 1446 1489 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="15">Novel mutations in the gene encoding TDP-43</p>
###xml 1446 1489 1446 1489 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="15">Novel mutations in the gene encoding TDP-43</p></caption>
###xml 1489 1489 1489 1489 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="335_2008_9117_Tab1_HTML"/>
###xml 1611 1614 1611 1614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GRN</italic>
###xml 1630 1634 1630 1634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD1</italic>
###xml 1667 1671 1667 1671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAPT</italic>
###xml 1710 1718 1710 1718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHMP2B&#160;=</italic>
###xml 1751 1755 1751 1755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VAPB</italic>
###xml 1803 1806 1803 1806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANG</italic>
###xml 1821 1826 1821 1826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCTN1</italic>
###xml 1489 1838 1489 1838 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="16">SALS&#160;=&#160;sporadic amyotrophic lateral sclerosis; FALS&#160;=&#160;familial amyotrophic lateral sclerosis; MND&#160;=&#160;motor neuron disease; <italic>GRN</italic>&#160;=&#160;progranulin; <italic>SOD1</italic>&#160;=&#160;Cu/Zn superoxide dismutase 1; <italic>MAPT</italic>&#160;=&#160;microtubule-associated protein tau; <italic>CHMP2B&#160;=</italic>&#160;chromatin modifying protein 2B; <italic>VAPB</italic>&#160;=&#160;synaptobrevin-associated membrane protein B; <italic>ANG</italic>&#160;=&#160;angiogenin; <italic>DCTN1</italic>&#160;=&#160;dynactin.</p>
###xml 1979 1985 1979 1985 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TARDBP</italic>
###xml 1838 2047 1838 2047 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="17">Each mutation is absent in the control group. Fourteen missense mutations lie in the glycine-rich domain of the protein encoded by exon 6 of <italic>TARDBP</italic> and one mutation lies in the first RNA binding domain (D169G)</p>
###xml 2047 2048 2047 2048 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 2067 2068 2067 2068 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 2118 2119 2118 2119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 2140 2141 2140 2141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 2218 2219 2218 2219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 2242 2243 2242 2243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 2278 2279 2278 2279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f</sup>
###xml 2314 2315 2314 2315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">s</sup>
###xml 2047 2362 2047 2362 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18"><sup>1</sup>mean age of onset, <sup>2</sup>FTLD and related disorders, see text for details, <sup>3</sup>all exons sequenced, <sup>4</sup>only the specific variants were analyzed, full sequencing was not performed, <sup>5</sup>only exon 6 sequenced, <sup>6</sup>method of detection not described, <sup>f</sup>mutation found in familial ALS, or <sup>s</sup>individuals with no known family history of ALS</p>
###xml 1489 2362 1489 2362 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="16">SALS&#160;=&#160;sporadic amyotrophic lateral sclerosis; FALS&#160;=&#160;familial amyotrophic lateral sclerosis; MND&#160;=&#160;motor neuron disease; <italic>GRN</italic>&#160;=&#160;progranulin; <italic>SOD1</italic>&#160;=&#160;Cu/Zn superoxide dismutase 1; <italic>MAPT</italic>&#160;=&#160;microtubule-associated protein tau; <italic>CHMP2B&#160;=</italic>&#160;chromatin modifying protein 2B; <italic>VAPB</italic>&#160;=&#160;synaptobrevin-associated membrane protein B; <italic>ANG</italic>&#160;=&#160;angiogenin; <italic>DCTN1</italic>&#160;=&#160;dynactin.</p><p textid="17">Each mutation is absent in the control group. Fourteen missense mutations lie in the glycine-rich domain of the protein encoded by exon 6 of <italic>TARDBP</italic> and one mutation lies in the first RNA binding domain (D169G)</p><p textid="18"><sup>1</sup>mean age of onset, <sup>2</sup>FTLD and related disorders, see text for details, <sup>3</sup>all exons sequenced, <sup>4</sup>only the specific variants were analyzed, full sequencing was not performed, <sup>5</sup>only exon 6 sequenced, <sup>6</sup>method of detection not described, <sup>f</sup>mutation found in familial ALS, or <sup>s</sup>individuals with no known family history of ALS</p></table-wrap-foot>
###xml 1439 2362 1439 2362 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="15">Novel mutations in the gene encoding TDP-43</p></caption><graphic xlink:href="335_2008_9117_Tab1_HTML"/><table-wrap-foot><p textid="16">SALS&#160;=&#160;sporadic amyotrophic lateral sclerosis; FALS&#160;=&#160;familial amyotrophic lateral sclerosis; MND&#160;=&#160;motor neuron disease; <italic>GRN</italic>&#160;=&#160;progranulin; <italic>SOD1</italic>&#160;=&#160;Cu/Zn superoxide dismutase 1; <italic>MAPT</italic>&#160;=&#160;microtubule-associated protein tau; <italic>CHMP2B&#160;=</italic>&#160;chromatin modifying protein 2B; <italic>VAPB</italic>&#160;=&#160;synaptobrevin-associated membrane protein B; <italic>ANG</italic>&#160;=&#160;angiogenin; <italic>DCTN1</italic>&#160;=&#160;dynactin.</p><p textid="17">Each mutation is absent in the control group. Fourteen missense mutations lie in the glycine-rich domain of the protein encoded by exon 6 of <italic>TARDBP</italic> and one mutation lies in the first RNA binding domain (D169G)</p><p textid="18"><sup>1</sup>mean age of onset, <sup>2</sup>FTLD and related disorders, see text for details, <sup>3</sup>all exons sequenced, <sup>4</sup>only the specific variants were analyzed, full sequencing was not performed, <sup>5</sup>only exon 6 sequenced, <sup>6</sup>method of detection not described, <sup>f</sup>mutation found in familial ALS, or <sup>s</sup>individuals with no known family history of ALS</p></table-wrap-foot></table-wrap>
###xml 94 101 <span type="species:ncbi:9606">patient</span>
###xml 637 645 <span type="species:ncbi:9606">patients</span>
The identification of TDP-43 in ALS and FTLD-U inclusion bodies immediately led to surveys of patient cohorts to find either association with or mutations in the gene. All returned with negative results (e.g., see Gijselinck et al. 2007; Rollinson et al. 2007; Schumacher et al. 2007), leading to the reasonable conclusion that TDP-43 deposition may simply be a consequence of disease and therefore possibly of less interest in providing novel insight into the cause of these diseases. However, in 2008 all this has changed with the publication of five articles, all of which report rare TDP-43 mutations in sporadic and familial ALS in patients of different ethnicities (mainly but not exclusively Caucasian) (Gitcho et al. 2008; Kabashi et al. 2008; Sreedharan et al. 2008; Van Deerlin et al. 2008; Yokoseki et al. 2008). In summary (Fig. 1, Table 1), all the mutations lie in exon 6 except for one in exon 4. The FALS cases are autosomal dominant with some variability in presentation, bulbar and limb onset cases, some with more or less lower motor neuron loss and different ages of onset and rates of progression, but all fairly classic FALS. No dementia is found, although Kabashi et al. (2008) report apathy, major anxiety, and agitation in two individuals. For cases in which postmortems have been carried out, TDP-43 deposition has been found in the brains of affected individuals (Van Deerlin et al. 2008; Yokoseki et al. 2008). Table 1Novel mutations in the gene encoding TDP-43SALS = sporadic amyotrophic lateral sclerosis; FALS = familial amyotrophic lateral sclerosis; MND = motor neuron disease; GRN = progranulin; SOD1 = Cu/Zn superoxide dismutase 1; MAPT = microtubule-associated protein tau; CHMP2B = chromatin modifying protein 2B; VAPB = synaptobrevin-associated membrane protein B; ANG = angiogenin; DCTN1 = dynactin.Each mutation is absent in the control group. Fourteen missense mutations lie in the glycine-rich domain of the protein encoded by exon 6 of TARDBP and one mutation lies in the first RNA binding domain (D169G)1mean age of onset, 2FTLD and related disorders, see text for details, 3all exons sequenced, 4only the specific variants were analyzed, full sequencing was not performed, 5only exon 6 sequenced, 6method of detection not described, fmutation found in familial ALS, or sindividuals with no known family history of ALS
###end p 14
###begin p 15
Novel mutations in the gene encoding TDP-43
###end p 15
###begin p 16
###xml 122 125 122 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GRN</italic>
###xml 141 145 141 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD1</italic>
###xml 178 182 178 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAPT</italic>
###xml 221 229 221 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CHMP2B&#160;=</italic>
###xml 262 266 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VAPB</italic>
###xml 314 317 314 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ANG</italic>
###xml 332 337 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DCTN1</italic>
SALS = sporadic amyotrophic lateral sclerosis; FALS = familial amyotrophic lateral sclerosis; MND = motor neuron disease; GRN = progranulin; SOD1 = Cu/Zn superoxide dismutase 1; MAPT = microtubule-associated protein tau; CHMP2B = chromatin modifying protein 2B; VAPB = synaptobrevin-associated membrane protein B; ANG = angiogenin; DCTN1 = dynactin.
###end p 16
###begin p 17
###xml 141 147 141 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TARDBP</italic>
Each mutation is absent in the control group. Fourteen missense mutations lie in the glycine-rich domain of the protein encoded by exon 6 of TARDBP and one mutation lies in the first RNA binding domain (D169G)
###end p 17
###begin p 18
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
###xml 20 21 20 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 71 72 71 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 93 94 93 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4</sup>
###xml 171 172 171 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5</sup>
###xml 195 196 195 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 231 232 231 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f</sup>
###xml 267 268 267 268 <sup xmlns:xlink="http://www.w3.org/1999/xlink">s</sup>
1mean age of onset, 2FTLD and related disorders, see text for details, 3all exons sequenced, 4only the specific variants were analyzed, full sequencing was not performed, 5only exon 6 sequenced, 6method of detection not described, fmutation found in familial ALS, or sindividuals with no known family history of ALS
###end p 18
###begin p 19
###xml 89 93 89 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2008</xref>
###xml 110 114 110 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2008</xref>
###xml 134 138 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">2008</xref>
###xml 159 163 159 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR51">2008</xref>
###xml 181 185 181 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">2008</xref>
###xml 606 610 606 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">2008</xref>
###xml 943 947 943 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2008</xref>
###xml 967 971 967 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">2008</xref>
###xml 989 993 989 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR54">2008</xref>
###xml 1096 1100 1096 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2008</xref>
###xml 1395 1399 1395 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">2008</xref>
###xml 762 769 <span type="species:ncbi:9606">patient</span>
###xml 1175 1180 <span type="species:ncbi:9031">chick</span>
The mutations are already starting to give some insight into pathogenesis (Gitcho et al. 2008; Kabashi et al. 2008; Sreedharan et al. 2008; Van Deerlin et al. 2008; Yokoseki et al. 2008). Disruption of protein interactions is one possible disease mechanism. Most mutations lie in the C-terminal, a glycine-rich region that may mediate interactions with proteins, including heterogeneous ribonucleoproteins. Also, some of the mutations found in this region could increase phosphorylation by substituting threonine or serine residues or through the creation of a new protein kinase A site (Sreedharan et al. 2008). This may result in disruption of protein interactions and/or disruption of transport through the nuclear pore complex. In transfected cell lines and patient lymphocytes some variants also show a clearly increased propensity to aggregate and to produce a lower-molecular-weight, detergent-insoluble protein product (Kabashi et al. 2008; Sreedharan et al. 2008; Yokoseki et al. 2008). One mutation, D169G, lies in the first RNA-binding motif and may affect RNA binding (Kabashi et al. 2008). When mutant TDP-43 is electroporated into the neural tube of developing chick embryos, two different mutations showed a reduction in rate of maturation of the neural tube with an increase in apoptotic nuclei, suggesting a toxic gain of function or dominant negative effect (Sreedharan et al. 2008).
###end p 19
###begin p 20
###xml 468 472 468 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2008</xref>
###xml 565 569 565 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2008</xref>
###xml 731 735 731 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR47">2008</xref>
###xml 1262 1266 1262 1266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2001</xref>
It is noteworthy that just one mutation lies in exon 4, within the first RNA recognition motif (RRM 1), whereas the other 13 mutations identified so far occur in exon 6, in the putative protein interaction domain. This raises the question of whether the exon 4 mutation (D169G) is a genuine pathogenic mutation and, if so, if it leads to disease via a different effect on TDP-43 function than the other mutations. D169 is a highly conserved amino acid (Kabashi et al. 2008) and the mutation was absent in 360 ethnically matched controls from France (Kabashi et al. 2008), as well as in 872 nonethnically matched controls (700 British, 172 Australian) for which all exons of TDP-43 were sequenced in the study of Sreedharan et al. (2008). The absence of the mutation in a large number of controls and the evolutionary conservation of the amino acid argue for a pathogenic role; however, absence in a larger number of ethnically matched controls and functional data or the identification of further mutations in RRM 1 will be required to fully resolve this issue. If D169G is pathogenic, then it suggests that mutations in the C-terminal domain, and the RRM1 domain, which has been shown to be essential for the RNA-binding ability of TDP-43 (Buratti and Baralle. 2001), affect the function of TDP-43 in a similar way, such as a general loss of function, or that there are different ways to disrupt TDP-43 function and still lead to disease.
###end p 20
###begin title 21
Rare single-gene defects, protein aggregates, and neurodegeneration-sounds familiar
###end title 21
###begin p 22
###xml 385 388 385 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APP</italic>
###xml 533 537 533 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2002</xref>
###xml 1106 1110 <span type="species:ncbi:10090">mice</span>
The identification of the major protein in neurodegenerative disease inclusion bodies, followed by finding rare mutations in the gene encoding this protein, is a powerful route to understanding pathogenesis and is turning into a surprisingly common approach in neurodegenerative diseases. It is exemplified by the classic example of finding mutations in the amyloid precursor protein (APP) gene that encodes the Abeta peptide deposited in the plaques of Alzheimer disease; it revolutionized our understanding of AD (Hardy and Selkoe 2002). Similar rare dominant single-gene mutations have also been found in the proteins that aggregate in Parkinson disease, prion diseases, and tauopathies, for example, also giving us great insight into the pathogenesis of these disorders. The articles that reported on TDP-43 mutations in ALS have shifted the focus of attention on this protein from being deposited as a by-product of disease processes to actually being a causative agent that triggers the processes resulting in neuronal death. From this point investigations will proceed using transgenic and knockout mice and a variety of different cellular systems to understand the link between mutation and disease.
###end p 22
###begin p 23
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD1</italic>
Many questions need to be addressed, such as does TDP-43 take on a toxic gain of function when mutated in ALS, as happens with SOD1 mutations in ALS? Will TDP-43 mutations be found in cases of FTLD-U, and if not, why not? How important is timing? Does having a germline TDP-43 mutation give rise to ALS which might develop into FTLD-U if individuals lived long enough? Another question is: What separates TDP-43 ALS from SOD1 ALS? These two diseases are very similar at a clinical level, but clearly different pathways are affected for at least some of the pathogenesis. We assume that there are many parallel cellular pathways, which, if disrupted can lead to the same outcome. TDP-43 ALS and SOD1 ALS may allow the investigation of this phenomenon.
###end p 23
###begin p 24
The new mutations found in TDP-43 are a breakthrough for ALS and FTLD-U research and we are looking forward to seeing what new discoveries they herald to help us treat and ultimately cure these terrible neurodegenerative diseases.
###end p 24
###begin p 25
###xml 189 194 <span type="species:ncbi:9606">human</span>
###xml 198 203 <span type="species:ncbi:10090">mouse</span>
For brevity we have cited recent review articles rather than original literature. Also, we have used the most frequently used abbreviation for the TDP-43 protein, which does not conform to human or mouse gene nomenclature rules. We thank Simon Mead and James Stevens for comments and Ray Young for graphics. These authors are supported by the Wellcome Trust, the ENDOCYTE Research and Training Network funded by the European Union, and the UK Medical Research Council.
###end p 25
###begin p 26
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 26
###begin title 27
References
###end title 27
###begin article-title 28
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
###end article-title 28
###begin article-title 29
TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
###end article-title 29
###begin article-title 30
###xml 7 17 7 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila</italic>
###xml 23 33 23 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C. elegans</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 7 17 <span type="species:ncbi:7227">Drosophila</span>
###xml 23 33 <span type="species:ncbi:238774|species:ncbi:386067|species:ncbi:147878|species:ncbi:193182|species:ncbi:313250|species:ncbi:323266|species:ncbi:315362|species:ncbi:148887|species:ncbi:124036|species:ncbi:48798|species:ncbi:529401|species:ncbi:314391|species:ncbi:646318|species:ncbi:254962|species:ncbi:323047|species:ncbi:287681|species:ncbi:269614|species:ncbi:103475|species:ncbi:114942|species:ncbi:212608|species:ncbi:457136|species:ncbi:227469|species:ncbi:449387|species:ncbi:551876|species:ncbi:248142|species:ncbi:252961|species:ncbi:466267|species:ncbi:119832|species:ncbi:228196|species:ncbi:316080|species:ncbi:217897|species:ncbi:109099|species:ncbi:328850|species:ncbi:266263|species:ncbi:348465|species:ncbi:181251|species:ncbi:6239|species:ncbi:320029|species:ncbi:293163|species:ncbi:4853|species:ncbi:160529|species:ncbi:292745|species:ncbi:368875|species:ncbi:323318|species:ncbi:209968|species:ncbi:405608|species:ncbi:480533">C. elegans</span>
Human, Drosophila, and C. elegans TDP43: nucleic acid binding properties and splicing regulatory function
###end article-title 30
###begin article-title 31
TDP-43 regulates retinoblastoma protein phosphorylation through the repression of cyclin-dependent kinase 6 expression
###end article-title 31
###begin article-title 32
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
###end article-title 32
###begin article-title 33
ALS: a disease of motor neurons and their nonneuronal neighbors
###end article-title 33
###begin article-title 34
Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9
###end article-title 34
###begin article-title 35
Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping
###end article-title 35
###begin article-title 36
TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions
###end article-title 36
###begin article-title 37
Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase
###end article-title 37
###begin article-title 38
Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease
###end article-title 38
###begin article-title 39
TDP-43: a novel neurodegenerative proteinopathy
###end article-title 39
###begin article-title 40
TAR-DNA binding protein 43 in Pick disease
###end article-title 40
###begin article-title 41
Pathological TDP-43 in parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam
###end article-title 41
###begin article-title 42
TDP-43 A315T mutation in familial motor neuron disease
###end article-title 42
###begin article-title 43
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics
###end article-title 43
###begin article-title 44
###xml 41 47 <span type="species:ncbi:9606">people</span>
The prevalence and causes of dementia in people under the age of 65 years
###end article-title 44
###begin article-title 45
TDP-43 is deposited in the Guam parkinsonism-dementia complex brains
###end article-title 45
###begin article-title 46
Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies
###end article-title 46
###begin article-title 47
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17
###end article-title 47
###begin article-title 48
###xml 2 7 <span type="species:ncbi:4932">yeast</span>
A yeast TDP-43 proteinopathy model: exploring the molecular determinants of TDP-43 aggregation and cellular toxicity
###end article-title 48
###begin article-title 49
TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis
###end article-title 49
###begin article-title 50
Involvement of the frontotemporal lobe and limbic system in amyotrophic lateral sclerosis: as assessed by serial computed tomography and magnetic resonance imaging
###end article-title 50
###begin article-title 51
TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis
###end article-title 51
###begin article-title 52
Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations
###end article-title 52
###begin article-title 53
The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments
###end article-title 53
###begin article-title 54
A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia
###end article-title 54
###begin article-title 55
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases
###end article-title 55
###begin article-title 56
Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria
###end article-title 56
###begin article-title 57
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
###end article-title 57
###begin article-title 58
TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions
###end article-title 58
###begin article-title 59
###xml 80 115 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs
###end article-title 59
###begin article-title 60
Molecular biology of amyotrophic lateral sclerosis: insights from genetics
###end article-title 60
###begin article-title 61
###xml 148 156 <span type="species:ncbi:9606">patients</span>
Frequency and clinical characteristics of progranulin mutation carriers in the Manchester frontotemporal lobar degeneration cohort: comparison with patients with MAPT and no known mutations
###end article-title 61
###begin article-title 62
Tau is a candidate gene for chromosome 17 frontotemporal dementia
###end article-title 62
###begin article-title 63
The prevalence of frontotemporal dementia
###end article-title 63
###begin article-title 64
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD1</italic>
###xml 44 59 <span type="species:ncbi:10090">transgenic mice</span>
Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS
###end article-title 64
###begin article-title 65
TDP-43 gene analysis in frontotemporal lobar degeneration
###end article-title 65
###begin article-title 66
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
###end article-title 66
###begin article-title 67
Genetics of sporadic amyotrophic lateral sclerosis
###end article-title 67
###begin article-title 68
Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia
###end article-title 68
###begin article-title 69
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
###end article-title 69
###begin article-title 70
TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis
###end article-title 70
###begin article-title 71
###xml 105 109 105 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SOD1</italic>
TDP-43 immunoreactivity in neuronal inclusions in familial amyotrophic lateral sclerosis with or without SOD1 gene mutation
###end article-title 71
###begin article-title 72
Three families with amyotrophic lateral sclerosis and frontotemporal dementia with evidence of linkage to chromosome 9p
###end article-title 72
###begin article-title 73
Genetics of familial amyotrophic lateral sclerosis
###end article-title 73
###begin article-title 74
TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis
###end article-title 74
###begin article-title 75
Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein
###end article-title 75
###begin article-title 76
Disturbance of nuclear and cytoplasmic Tar DNA binding protein (TDP-43) induces disease-like redistribution, sequestration and aggregate formation
###end article-title 76
###begin article-title 77
TDP-43 mutation in familial amyotrophic lateral sclerosis
###end article-title 77

